SCHEMBL3327642

SCHEMBL3327642

Cc1c(Cc2ccc(S(=O)(=O)N3CCOCC3)cc2)c2cc(C#N)ccn2c1CC(=O)O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
GAA P10253 3/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PTGDR2 Q9Y5Y4 3/20 0.44
ALB P02768 1/20 0.43
KMT2A Q03164 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
APEX1 P27695 1/20 0.40
MEN1 O00255 1/20 0.38
FGB P02675 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
PABPC1 P11940 1/20 0.38
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3332006 0.90 MAPK1 (0.43) ALDH1A1GAALMNASMN1; SMN2ALB
SCHEMBL3327423 0.89 CNR1 (0.39) ALDH1A1GAASMN1; SMN2PTGDR2
SCHEMBL4636233 0.85 PTGDR2 (0.41) PTGDR2
SCHEMBL4636220 0.84 ALB (0.43) ALDH1A1GAALMNASMN1; SMN2PTGDR2
SCHEMBL4431234 0.81 RORC (0.36) ALDH1A1PTGDR2
SCHEMBL3326854 0.80 KMT2A (0.40) ALDH1A1SMN1; SMN2KMT2ATDP1MEN1
SCHEMBL4636743 0.80 PTGES (0.38) ALDH1A1LMNAPTGDR2KMT2AMEN1
SCHEMBL4779100 0.79 TSHR (0.40) ALDH1A1SMN1; SMN2PTGDR2ALBKMT2A
SCHEMBL3324726 0.78 RORC (0.34) PTGDR2
SCHEMBL4563651 0.78 ALDH1A1 (0.46) ALDH1A1GAALMNASMN1; SMN2ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US claimed
EP-2136804-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Argenta Oral Therapeutics Limited (GB) 2009-12-30 EP claimed
WO-2008113965-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2008-09-25 WO claimed
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US disclosed
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US disclosed
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists ARGENTA ORAL THERAPEUTICS LIMITED (GB) 2010-06-03 US disclosed
CN-101678009-A Indolizine acetic acid derivatives as CRTH2 antagonists ARGENTA DISCOVERY LTD 2010-03-24 CN disclosed
EP-2136804-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Argenta Oral Therapeutics Limited (GB) 2009-12-30 EP disclosed
EP-2136804-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS Argenta Oral Therapeutics Limited (GB) 2009-12-30 EP disclosed
WO-2008113965-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2008-09-25 WO disclosed
WO-2008113965-A1 INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS ARGENTA DISCOVERY LIMITED (GB) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137300-A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists HRH1, HRH4, HRH2 ALDH1A1 744/4885GAA 2959/4885LMNA 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.